GHRH Analogue Peptide (Full-Length)

Tesamorelin

A 44-amino acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical research.

Compound Profile

Class: GHRH Analogue Peptide (Full-Length)
Origin: Synthetic analogue of endogenous Growth Hormone-Releasing Hormone (GHRH), retaining the full 44-amino acid active sequence with a trans-3-hexenoic acid modification at the N-terminus
Structure: 44 amino acids · N-terminal trans-3-hexenoic acid modification · Identical primary sequence to endogenous human GHRH(1-44) · Molecular weight ~5,136 Da
Purity: 99.6%
Format: Lyophilized powder
Lot: NLR-202606

Overview

Tesamorelin is a synthetic analogue of human Growth Hormone-Releasing Hormone (GHRH), a 44-amino acid hypothalamic peptide that stimulates pituitary somatotroph cells to secrete growth hormone (GH) via the GHRH receptor (GHRHR), a Gs-protein-coupled receptor. Unlike CJC-1295 (a truncated GHRH(1-29) analogue), tesamorelin retains the full 44-amino acid sequence of the endogenous hormone with an N-terminal trans-3-hexenoic acid modification that improves resistance to plasma dipeptidyl peptidase IV (DPP-IV) degradation. As a research compound, tesamorelin is used to study GHRH receptor binding kinetics, hypothalamic-pituitary GH axis signaling, and metabolic effects of GHRH receptor activation in preclinical and in vitro models.

Key Facts

Retains full 44-amino acid sequence of endogenous human GHRH, unlike CJC-1295 which is based on the truncated GHRH(1-29) fragment
N-terminal trans-3-hexenoic acid modification increases resistance to DPP-IV proteolytic cleavage compared to native GHRH
GHRH receptor (GHRHR) is a class B G-protein-coupled receptor expressed predominantly on pituitary somatotrophs; activation stimulates cAMP–PKA signaling and GH release
Endogenous GHRH is secreted in pulsatile fashion from the arcuate nucleus of the hypothalamus and is rapidly degraded in plasma (t½ < 5 min for native GHRH)
Studied in published clinical research for effects on visceral adipose tissue in the context of metabolic research; that research used pharmaceutical-grade formulations under clinical trial conditions, which are distinct from this RUO compound
Lyophilized; reconstituted with bacteriostatic water for in vitro or animal model studies
For research use only — not for human or veterinary administration

Published Research

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

Journal of Acquired Immune Deficiency Syndromes · 2010 · NCBI

Metabolic effects of a growth hormone-releasing factor in patients with HIV

New England Journal of Medicine · 2007 · NCBI

Tesamorelin, a growth hormone-releasing factor analogue, for the treatment of HIV-associated lipodystrophy: mechanisms and clinical perspectives

Expert Opinion on Pharmacotherapy · 2011 · NCBI

For laboratory and research use only. This compound is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use.